IBAB Ion Beam Applications SA

ElsMed, Novatec and IBA sign contract to install radiopharmaceutical production center in Georgia

ElsMed, Novatec and IBA sign contract to install radiopharmaceutical production center in Georgia

The center will be equipped with a Cyclone® KIUBE offering the highest production capacity with a PET cyclotron.

Louvain-La-Neuve, Belgium, October 4, 2022 –  (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, Novatec International and ElsMed Healthcare Solutions, the leading Israeli medical-technological company, announced today that they have signed a contract for the installation of an integrated radiopharmaceutical production facility in Tbilisi, Georgia.

The project will be the first of its kind in Georgia and includes the construction of an ultra-modern radiopharmaceutical facility equipped with the latest technologies such as the IBA’s Cyclone® KIUBE and Synthera®+ platform. The center will produce various types of radiopharmaceutical products and is expected to start operations in 2024.

The design, construction, operation, and production processes of the facility will be developed in line with the International Atomic Energy Agency (IAEA) standards and recommendations from IBA, as well as meeting set requirements defined by the legislation of Georgia.

The General Director of Novatec International, Giorgi Glonti, commented: “This unique project for an on-site production facility for radiopharmaceutical compounds will significantly boost the development of nuclear medicine in the country of Georgia. This initiative will also contribute to increasing the availability of Positron-Emission Computed Tomography (PET-CT) for a wider population. The facility will be able to fully cover the current and future demand of the Georgian market, both in terms of production and delivery of fluorodeoxyglucose (18F-FDG) as well as other artificial radioactive isotopes.”

“Nowadays, radiopharmacies need to produce an increasing amount of FDG in a limited time frame, in addition to producing numerous other compounds. The Cyclone® KIUBE is the perfect solution providing the ability to produce the widest range of radioisotopes and covers all the needs of PET radiopharmacies,” said Bruno Scutnaire, President of IBA RadioPharma Solutions.

Hen Lederman, General Manager of the ElsMed Healthcare Solutions added: “We are pleased to participate in a such unique and useful project. Our joint efforts will have a significantly positive effect in the fight against cancer in Georgia, with ElsMed being additionally involved in the facility design and training of necessary personnel, in cooperation with leading nuclear medicine centers in Israel, and will provide continuous support until project completion.”

***ENDS***

About Novatec International

Novatec International LLC is a Georgian company founded to create and develop a radiopharmaceutical production in order to fulfill Georgia demand for various PET CT isotopes. The main stakeholders of the Novatec International are well known in Eastern Europe countries healthcare sector with experience in establishing a state-of-the-art medical center.

About ElsMed

ElsMed Healthcare Solutions Ltd. is a leading well-known company providing turnkey solutions including establishment of complete medical centers worldwide as well as oncology centers and other various ventures in the medical field with international standards. The essence of the company’s operations is to provide the latest and most advanced medical services to populations worldwide with an active involvement.

The company’s main activities are focused on establishing, managing and maintaining turnkey medical projects starting from the development stage through the planning, building, procurement, technical and medical training as well as routine operations and mainly after sale ongoing service support. ElsMed Healthcare Solution has assembled the best and most qualified professionals in all disciplines: consultants, architects, engineers, project managers, financial experts, technologists and medical technicians, physicians, proving track record in the establishment of medical projects internationally.

Please visit our website for more information:

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,600 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

CONTACTS

Soumya Chandramouli

Chief Financial Officer







 



Olivier Lechien

Corporate Communication Director



Consilium Strategic Communications

Amber Fennell, Angela Gray, Lucy Featherstone

+44 (0) 20 3709 5700





 

Attachment



EN
04/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE

IBA – Transparency Notification

IBA – Transparency Notification (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve (Belgium), 22 September 2025, 06:00 PM Summary of the notification IBA (Ion Beam Applications S.A - EURONEXT - Reuters IBAB.BR - Bloomberg IBAB.BB), the world leader in particle accelerator technology, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to a notification dated Tuesday 16 September 2025 and received on Thursday ...

 PRESS RELEASE

IBA SA – NOTIFICATION TRANSPARENCE

IBA SA – NOTIFICATION TRANSPARENCE (Article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve (Belgique), le 22 septembre 2025, 18h00 Résumé de la notification IBA (Ion Beam Applications S.A. - EURONEXT - Reuters IBAB.BR - Bloomberg IBAB.BB), le leader mondial de la technologie d’accélération de particules, annonce devoir effectuer une notification en matière de transparence conformément à l'article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes (« loi transparence »), à la sui...

 PRESS RELEASE

IBA – TRANSPARENCY NOTIFICATION

IBA – TRANSPARENCY NOTIFICATION (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, September 10, 2025 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on September 3, 2025. In its notification, Marcel Jo Maschmeyer ind...

 PRESS RELEASE

IBA SA – NOTIFICATION TRANSPARENCE

IBA SA – NOTIFICATION TRANSPARENCE (article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 10 septembre 2025, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce devoir effectuer une notification en matière de transparence conformément à l'article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes (« loi transparence »), à la suite d’une notification reçu...

Michiel Declercq
  • Michiel Declercq

IBA 1H25 Conference call feedback & model update

IBA reported good 1H25 results, with revenues up 40% to € 304.9m (kbcse: € 274.6m) driven by strong backlog conversion in PT as well as OA. However, as most of the conversion relates to legacy lower margin contracts in Spain and China, the gross profit increase of +27% to € 90.0m (kbcse: € 93.4m) and REBIT of € 10.6m (kbcse: € 10.3m) were broadly in line with our estimates. However net cash significantly deteriorated on the back of WC investments, as anticipated. We are pleased to see IBA reiter...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch